Indeed, when considering only rare-disease probands with advanced kidney disease (recruited in GE100kGP under the keywords “end-stage kidney disease,” chronic kidney disease stage 4,” and “chronic kidney disease stage 5”), the yield of homozygous deletions in NPHP1 is ∼1.2% (11 homozygous NPHP1 deletions out of 959 probands with advanced kidney disease). This evidence concerns the gene NPHP1 and stage 5 chronic kidney disease.